From Medscape Psychiatry

Coverage from the

Anxiety and Depression Association of America (ADAA) 2019

March 28 - 31, 2019; Chicago, Illinois

March 28 - 31, 2019 Chicago, Illinois

ADAA 2019 Disturbed Sleeps Derails Therapy for Complicated Grief Cognitive grief treatment surpasses antidepressants alone for complicated grief, but sleep disturbances, which are common, can derail treatment.
Medscape Medical News, April 9, 2019
ADAA 2019 Ketamine a Panacea for Resistant Depression? Not So Fast Reports of relapses and suicides are tempering some of the earlier excitement over ketamine's much-needed rapid relief for patients with severe depression.
Medscape Medical News, April 4, 2019
ADAA 2019 Songwriting May Hit the Right Therapeutic Note in PTSD A novel songwriting program takes music therapy from passive to active engagement ? with significant therapeutic potential in patients with posttraumatic stress disorder, new research suggests.
Medscape Medical News, April 3, 2019

Conference News

ADAA 2019 Novel Suicide Prediction Tool Goes Beyond Patient Self-Reports
Medscape Medical News, April 15, 2019
ADAA 2019 Disturbed Sleeps Derails Therapy for Complicated Grief
Medscape Medical News, April 9, 2019
ADAA 2019 Ketamine a Panacea for Resistant Depression? Not So Fast
Medscape Medical News, April 4, 2019

ADAA 2019 Songwriting May Hit the Right Therapeutic Note in PTSD
Medscape Medical News, April 3, 2019
ADAA 2019 Immunosuppressant May Extend Ketamine's Antidepressant Effects
Medscape Medical News, April 2, 2019
ADAA 2019 Combination Therapy for PTSD Provides No Added Benefit
Medscape Medical News, April 1, 2019

Popular News from ADAA 2018

Few Psychiatrists Recommend Exercise for Anxiety Disorders Although even short, intense exercise can benefit patients with anxiety disorders, most psychiatrists don’t discuss or recommend this effective intervention, new research shows.
Medscape Medical News, Apr 10, 2018
Lurasidone Appears Safe in Kids With Bipolar Depression Lurasidone, approved for bipolar depression in children and adolescents on the basis of 6-week findings from a phase 3 trial, is also safe and effective for up to 28 weeks, new open-label data show.
Medscape Medical News, Apr 18, 2018
Ketamine: Key Predictor of Treatment Response for MDD Identified More intense dissociative symptoms during ketamine infusion for severe depression, particularly depersonalization, may be a key predictor of treatment response.
Medscape Medical News, Apr 12, 2018

Medscape Psychiatry© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage